2nd Annual MarketsandMarkets

Real-World Evidence and Market Access Conference

14th - 15th October 2024

Freiburg im Breisgau, Germany

Unlocking Insights, Driving Access: Bridging Real-World Evidence to Market Success in Europe

Join us at the MarketsandMarkets 2nd Annual Real-World Evidence and Market Access Conference, October 2024, Freiburg im Breisgau, Germany edition to be at the forefront of driving transformative change in healthcare.

This gathering serves a platform where industry leaders, healthcare professionals, and policymakers converge to explore the latest trends, challenges, and innovations shaping the dynamic landscape of evidence-based healthcare and market access strategies. Through engaging keynotes, interactive panel discussions, and networking opportunities, this event aims to foster collaboration, share best practices, and catalyze advancements that drive improved patient outcomes and successful market access across the European healthcare ecosystem.

WHAT TO EXPECT

  • Updates on European regulatory frameworks governing real-world evidence (RWE) and their impact on market access strategies.
  • Ensuring the reliability, validity, and relevance of RWE in the context of market access.
  • Effective collaboration strategies between industry stakeholders and payers to enhance market access outcomes.
  • Strategies for pricing and reimbursement that align with evidence-based market access approaches.
  • The impact of patient-reported outcomes on demonstrating product value and effectiveness.
  • The role of health economics in demonstrating the economic value of healthcare interventions.

  • Learn about the recent trends and advancements in Real-World Evidence Generation
  • Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

  • Real-World Evidence
  • Real-World Data
  • Data Analytics
  • Health Economics & Outcomes Research- HEOR
  • Market Access/Value Access
  • Policy
  • Clinical Development & research
  • Clinical trial
  • Centre for Observational and Real-World Evidence  
  • Epidemiology
  • Oncology-RWE
  • Pricing and Reimbursement
  • Medical Affairs
  • Pharmacovigilance
  • Life Science Analytics
  • Big data
  • Data Science
  • Bio-Statistics
  • Consumer Healthcare

Other

Payers, Regulators, Research Institutes, and Innovation Centre

CONFERENCE AGENDA

Registration

08:15 - 09:00

Welcome note by MarketsandMarkets

09:00 - 09:05

Opening remarks by the Chairperson

09:05 - 09:10

Data Quality and Standardization

Ensuring the reliability and quality of real-world data used in RCTs.

09:10 - 09:40

RWE in the EU Joint Clinical Assessment- Opportunities and Challenges?

Sandeep Kiri

Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB

09:40 - 10:10

Electronic Health Record meets Evidence

Ralf Patsch

Ralf Patsch, Head of Real-World Data Business Germany, Cegedim

10:10 - 10:40

Morning Refreshments and Poster Presentation | One-to-One Networking Meeting

10:40 - 11:30

RWE for Health Technology Assessment (HTA)

Sponsor Presentation – Slot Reserved for Gold/Silver Sponsors- Flatiron

11:30 - 12:00

The Statistical Abyss that is RWE for HTA

Martin Scott

Martin Scott, Scientific Director, Numerus

12:00 - 12:30

Methodological considerations with the development and implementation of external control arms using routine electronic health records

Lewis Carpenter

Lewis Carpenter, Director Real World Evidence, Arcturis Data

12:30 - 13:00

Lunch and Poster Presentation | One-to-One Networking

13:00 - 14:00

Post-Marketing Surveillance and Phase IV Trials

Population adjusted RCTs – an option for long-term comparisons?

Michael Happich

Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company

14:00 - 14:30

Sponsor Presentation – Slot Reserved for Silver/Bronze Sponsors

14:30 - 15:00

Panel Discussion- RWE in assessing long-term safety and effectiveness of interventions.

15:00 - 15:40

Evening Refreshments and Poster Presentation | One-to-One Networking

15:40 - 16:25

Patient Recruitment and Retention

Bridging the chasm between successful clinical trials and long-term Benefit/Risk and medico-economic impact demonstration: towards mutualized disease-centric cohort simulators

Alexandre Templier

Alexandre Templier, Co-founder and President, Quinten Health

16:25 - 16:55

Real world influence of real world evidence for policy decision making at NICE’

Vandana Ayyar-Gupta

Vandana Ayyar-Gupta, Scientific Adviser, Data & Analytics, National Institute for Health, and Care Excellence

16:55 - 17:25

Drinks Reception and Networking .....END OF DAY 1.....

17:25 - 17:25

Registration

08:15 - 08:50

Welcome note by MarketsandMarkets

08:50 - 09:05

Opening remarks by the Chairperson

09:05 - 09:10

Patient-Centric Market Access

Utilizing patient-reported outcomes (PROs) and patient-centric RWE

09:10 - 09:40

Sponsor Presentation – Slot Reserved for Gold / Silver Sponsors

09:40 - 10:10

Comparative retrospective RWE database studies: why and how to do them

Thomas Wilke

Thomas Wilke, Senior Scientist, GIPAM Health

10:10 - 10:45

Morning Refreshments and Poster Presentation | One-to-One Networking

10:45 - 11:30

RWE in Market Access for Rare Diseases & Other Medical Conditions

Evidence Appraisal and Public Health decision-making in a post-pandemic era: insights from the world of vaccines.

Gustavo Olivera

Gustavo Olivera, HEOR (Health Economics & Outcomes Research) Senior Expert, Sanofi

11:30 - 12:00

Sponsor Presentation – Slot Reserved for Bronze Sponsors

12:00 - 12:30

Joint Clinical Assessment: Getting there and moving from there

Remon Helmy

Remon Helmy, Senior Manager, Global Health Economics & Outcomes Research (HEOR), Alexion Pharmaceuticals

12:40 - 13:00

Closing remarks by the chairperson

13:00 - 13:15

Lunch and Poster Presentation | One-to-One Networking

13:15 - 13:15

SPEAKERS

Sandeep Kiri

Sandeep Kiri

UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB

Michael Happich

Michael Happich

Sr Director HTA, International Markets, Eli Lilly and Company

Senior representatives, Quentin Health

Senior representatives, Quentin Health

,

Inha Kim

Inha Kim

Vice President, Head of Global Strategy and Communication, Medical Affairs,, Lundbeck

Vandana Ayyar-Gupta

Vandana Ayyar-Gupta

Scientific Adviser, Data & Analytics, National Institute for Health, and Care Excellence

Iroda Jurabekova

Iroda Jurabekova

Global Pricing and Market Access Lead, Boehringer Ingelheim

Ralf Patsch

Ralf Patsch

Head of Real-World Data Business Germany, Cegedim

Senior Representative, Flatiron Health

Senior Representative, Flatiron Health

,

Senior Representative, Cascador Health

Senior Representative, Cascador Health

,

Helene Vioix

Helene Vioix

Director Global Evidence & Value Development Oncology, Merck KGaA

Martin Scott

Martin Scott

Scientific Director, Numerus

Lewis Carpenter

Lewis Carpenter

Director Real World Evidence, Arcturis Data

Gustavo Olivera

Gustavo Olivera

HEOR (Health Economics & Outcomes Research) Senior Expert, Sanofi

Craig Currie

Craig Currie

Honorary Professor of Pharmacoepidemiology, Cardiff University

Rocío Casado Seminario

Rocío Casado Seminario

European Affairs and Evidence Generation Head, , European Cancer Organisation (ECO)

Sabrina de Souza

Sabrina de Souza

Associate Director, Real World Data Scientist (CMS, PRWE), Merck

Donia Bahloul

Donia Bahloul

Global and US HEOR Business Partner, Global Health Economics & Value Assessment, Sanofi

José-Tomás Prieto

José-Tomás Prieto

AI programs Lead, Apheris

Alexandre Templier

Alexandre Templier

Co-founder and President, Quinten Health

Thomas Wilke

Thomas Wilke

Senior Scientist, GIPAM Health

ENQUIRE NOW

SPONSORS

LOCATION

Venue

Freiburg im Breisgau, Germany

PAST EVENT GALLERY